Clinical Trials in the UK / NCT07033598
Recruiting
Phase 2
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07033598 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Leukemia, Myelomonocytic, Chronic
Investigational drug(s) / intervention(s)
Pacritinib: 100-mg capsules
Hydroxyurea: capsules or tablets
Study summary
The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are:
* Does pacritinib improve disease control compared to hydroxyurea?
* What medical problems do participants have when taking pacritinib or hydroxyurea? Researchers will compare pacritinib to hydroxyurea to see if pacritinib is more effective and better tolerated in people with advanced proliferative chronic myelomonocytic leukemia.
Participants will be randomly assigned to receive either pacritinib twice a day or hydroxyurea for up to 48 weeks.
After treatment ends, participants will be followed for up to one year.
Eligibility
Inclusion Criteria:
* Diagnosis of CMML-1 (5th WHO classification), with \<10% bone marrow blasts on morphology and \<5% peripheral blood blasts.
* Proliferative disease, defined as white blood cell count ≥13 × 10⁹/L.
* Advanced disease, defined as at least one of the following features during screening: spleen palpable ≥5cm below the lower costal margin in the midclavicular line; TSS ≥20; or platelet count \<100 × 10⁹/L. For participants in whom spleen palpation is not feasible, an ultrasound exam may be performed for assessment of spleen craniocaudal length (length ≥12 cm by ultrasound is considered splenomegaly).
* ECOG performance status ≤2.
* Adequate organ function: AST and ALT ≤3 × ULN, total bilirubin ≤4 × ULN (≤8 × ULN in participants with Gilbert's syndrome), creatinine clearance \>30 mL/min, absolute neutrophil count ≥0.5 × 10⁹/L, PT and PTT ≤1.5 × ULN.
* Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrollment and, along with male participants, must agree to use a highly effective method of contraception from the first dose through 90 days after the last dose.
Exclusion Criteria:
* Active malignancy diagnosed within the past 2 years, except for curatively treated non-invasive cancers (e.g., basal/squamous cell skin cancer, low-risk prostate cancer on stable endocrine therapy with PSA stable ≥3 months).
* Allogeneic hematopoietic stem cell transplant within 12 months prior to enrollment, or requiring immunosuppressive therapy within 6 months before enrollment.
* Likely to undergo allogeneic hematopoietic stem cell transplant within 6 months, per investigator assessment.
* Prior systemic treatment with any JAK inhibitor.
* Treatment with hypomethylating agents or cytotoxic chemotherapy (excluding hydroxyurea) within 28 days prior to enrollment.
* Participation in another interventional study or use of experimental therapy within 28 days or 5 half-lives, whichever is longer.
* Use of hematologic support drugs within 28 days prior to enrollment. Supportive care permitted.
* Use of strong CYP3A4 inhibitors or inducers within 14 days or 5 half-lives before enrollment, whichever is shorter.
* Use of systemic anticoagulants or antiplatelets (except aspirin ≤100 mg/day) within 14 days prior. Therapeutic anticoagulation allowed if stable for ≥90 days without bleeding events.
* CTCAE Grade ≥2 bleeding within 3 months prior to enrollment, unless due to a reversible cause (e.g., trauma, surgery).
* QTcF \>450 ms (men) or \>470 ms (women); QTcF up to 480 ms allowed if QRS \>100 ms. QTcF may be repeated if affected by reversible factors.
* CTCAE Grade ≥3 cardiac event within 3 months before enrollment.
* Symptomatic heart failure with limitations on ordinary activity.
* Uncontrolled infection at study entry.
* Moderate/severe hepatic impairment (Child-Pugh B or C), or active viral hepatitis:
* HBV: Exclude if HBsAg+ or HBV DNA detectable. HBV antiviral therapy allowed if HBV DNA undetectable.
* HCV: Allowed if HCV Ab+ but RNA negative.
* Uncontrolled HIV or detectable viral load while on antiretrovirals.
* Known hypersensitivity to pacritinib or its excipients (microcrystalline cellulose, polyethylene glycol, magnesium stearate).
Primary outcome measure(s)
- Clinical benefit at Week 24, defined as achieving erythroid response in the absence of leukemic transformation. — Measured from Week 24 through the end of treatment, up to 48 weeks.
For participants with baseline hemoglobin \<10 g/dL, response is defined as either a ≥1.5 g/dL hemoglobin increase lasting ≥8 weeks without red blood cell transfusion, or, if transfusion-dependent at baseline (≥4 units in the 8 weeks pre-enrollment), achieving ≥8 weeks of red blood cell transfusion independence, excluding transfusions given for pretreatment Hb ≤8.5 g/dL. Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma. - Clinical benefit at Week 24, defined as achieving platelet response in the absence of leukemic transformation. — Measured from Week 24 through the end of treatment, up to 48 weeks.
For participants with baseline platelet counts \<100 × 10⁹/L, response is defined as one of the following: an increase to ≥20 × 10⁹/L and by ≥100% for ≥8 weeks without platelet transfusion (if baseline \<20 × 10⁹/L); an increase of ≥30 × 10⁹/L for ≥8 weeks without transfusion (if baseline 20-\<100 × 10⁹/L); or, if transfusion-dependent at baseline (≥4 units in the 8 weeks pre-enrollment), achieving ≥8 weeks of platelet transfusion independence. Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma. - Clinical benefit at Week 24, defined as achieving neutrophil response in the absence of leukemic transformation. — Measured from Week 24 through the end of treatment, up to 48 weeks.
For participants with baseline ANC ≤1 × 10⁹/L, response is defined as either an increase to \>0.5 × 10⁹/L and by ≥100% for ≥8 weeks without myeloid growth factors (if baseline ANC ≤0.5 × 10⁹/L), or an increase by ≥50% for ≥8 weeks without myeloid growth factors (if baseline ANC \>0.5 to ≤1 × 10⁹/L). Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma. - Clinical benefit at Week 24, defined as achieving spleen response in the absence of leukemic transformation. — Measured from Week 24 through the end of treatment, up to 48 weeks.
For participants with baseline spleen ≥5 cm below the left costal margin (midclavicular line), spleen response is defined as a ≥35% reduction in spleen volume at endpoint assessment by MRI or CT. Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma. - Clinical benefit at Week 24, defined as achieving symptom response in the absence of leukemic transformation. — Measured from Week 24 through the end of treatment, up to 48 weeks.
Among participants with baseline Total Symptom Score (TSS) ≥20 per the MPN-SAF TSS: achieving ≥50% TSS reduction from baseline at the time of endpoint assessment. Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | Recruiting |
| Winship Cancer Institute at Emory | Atlanta | Georgia | Recruiting |
| Mayo Clinic Rochester | Rochester | Minnesota | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | Recruiting |
| King's College Hospital, NHS Foundation Trust | London | Greater London | Recruiting |
| The Christie, NHS Foundation Trust | Manchester | Greater Manchester | Recruiting |
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07033598 on ClinicalTrials.gov ↗ ← All trials in the UK